Abstract: A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.

Abstract: Disclosed are oligonucleotides, compositions, and methods that may be useful in the treatment of age-related macular degeneration (AMD). The treatment of age-regulated macular degeneration (AMD) may involve inhibiting an miR-33 target nucleic acid. For example, inhibition of an miR-33 target nucleic acid may be achieved using antisense oligonucleotides targeting an miR-33 target nucleic acid, interfering oligonucleotides targeting an miR-33 target nucleic acid, or recombinant AAV particles including a vector encoding an antisense oligonucleotide or interfering oligonucleotide targeting an miR-33 target nucleic acid.

Abstract: The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.

Abstract: There are provided inter alia compounds capable of inhibiting retinal pigment epithelium (RPE) degeneration or geography atrophy (GA) associated with age-related macular degeneration (AMD), and methods of using the same.

Abstract: The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.

Abstract: The invention provides a solution to the clinical problem of retinal pigment epithelium (RPE) degeneration or geographic atrophy (GA) associated AMD. PPAR? selective agonists, e.g., troglitazone and analogs thereof are used to reduce or inhibit RPE degeneration, GA, and/or the progression of dry AMD.

Abstract: A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.

Abstract: Methods of treating acute thyroid eye disease (TED) by administering a inhibitor, e.g., a VEGF-A inhibitor, e.g., an anti-VEGF antibody, optionally in combination with hyaluronidase, by periorbital or intraorbital injection. Also compositions comprising a VEGF inhibitor and hyaluronidase.

Abstract: A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.

Abstract: There are provided inter alia compounds capable of inhibiting retinal pigment epithelium (RPE) degeneration or geography atrophy (GA) associated with age-related macular degeneration (AMD), and methods of using the same.

Abstract: The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.

Abstract: Methods of treating acute thyroid eye disease (TED) by administering a inhibitor, e.g., a VEGF-A inhibitor, e.g., an anti-VEGF antibody, optionally in combination with hyaluronidase, by periorbital or intraorbital injection. Also compositions comprising a VEGF inhibitor and hyaluronidase.

Abstract: The invention provides a solution to the clinical problem of retinal pigment epithelium (RPE) degeneration or geographic atrophy (GA) associated with AMD. PPAR? selective agonists, e.g., troglitazone and analogs thereof are used to reduce or inhibit RPE degeneration, GA, and/or the progression of dry AMD.

Abstract: A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.

Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory agent.

Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory agent.

Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory Agent

Abstract: The following disclosure provides compositions and methods for the repairing of a diseased or disordered retina, for example, in patients suffering from age-related macular degeneration (AMD).

Abstract: A novel series of articles useful as implants and prostheses and methods for their preparation and use are provided which utilize polyanhydride polymeric matrices as a general class of materials. These articles are biocompatible, non-inflammatory and degrade predictably into non-toxic residues after introduction in-vivo. The articles may be formed in any desired dimensions and configuration and may take specific shape as vascular or skin grafts, as biodegradable sutures or as orthopedic appliances such as bone plates and the like.

Abstract: A novel series of articles useful as implants and prostheses and methods for their preparation and use are provided which utilize polyanhydride polymeric matrices as a general class of materials. These articles are biocompatible, non-inflammatory and degrade predictably into non-toxic residues after introduction in-vivo. The articles may be formed in any desired dimensions and configuration and may take specific shape as vascular or skin grafts, as biodegradable sutures or as orthopedic appliances such as bone plates and the like.